Drug Profile
Adipose dreived allogeneic stem cell therapy - Regeneus
Alternative Names: PRG; Progenza™Latest Information Update: 21 Jul 2023
Price :
$50
*
At a glance
- Originator Regeneus ltd
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Cytokine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoarthritis
- Preclinical Neuropathic pain
Most Recent Events
- 20 Jul 2023 Preclinical development is ongoing for Neuropathic pain in Australia (Regeneus pipeline, July 2023)
- 02 Jan 2023 Adipose dreived allogeneic stem cell therapy is still in phase-II clinical trials for Osteoarthritis in Australia (Intra-articular) (Regeneus pipeline, January 2023)
- 05 Aug 2021 Regeneus and Genome Institute of Singapore enters into R&D agreement to improve efficiencies in adipose tissue donor selection